Suppr超能文献

全身糖皮质激素使用对骨折风险的影响:一项基于人群的研究。

Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.

机构信息

Inhu-Chongno Pharmacy, Jeonju, Korea.

Department of Pharmacy, Mediplex Sejong Hospital, Incheon, Korea.

出版信息

Endocrinol Metab (Seoul). 2020 Sep;35(3):562-570. doi: 10.3803/EnM.2020.659. Epub 2020 Sep 22.

Abstract

BACKGROUND

Long-term glucocorticoid use increases fracture risk by reducing bone mass. This study evaluated the relationship between hip and vertebral fractures and the total amount of systematic glucocorticoid use.

METHODS

We randomly selected 1,896,159 people aged 20 to 100 years who participated in the National Health Checkup program in 2006. The amount of glucocorticoids prescribed was calculated based on the defined daily dose (DDD). The total DDD was obtained by adding oral and parenteral glucocorticoids for 6 months from the index date. Subjects were categorized into four groups according to total glucocorticoid DDDs: non-users (DDDs=0), low users (0< DDDs ≤45), intermediate users (45< DDDs ≤90), and high users (90< DDDs). We followed them for 2 years. A multivariate Cox proportional hazard model was used to evaluate the effects of the total amount of glucocorticoid use on hip and vertebral fractures.

RESULTS

Higher glucocorticoid use was associated with a higher risk of vertebral fracture. Relative to non-users, the vertebral fracture risk was 1.39 times higher in the low-user group, 1.94 times higher in the intermediate-user group, and 2.43 times higher in the highuser group. The risk of hip fracture was 1.72 times higher in intermediate users and 3.28 times higher in high users than in non-users.

CONCLUSION

As the amount of glucocorticoid use for 6 months increased, the risk of hip and vertebral fractures became higher. In order to prevent fractures, it is necessary for doctors to evaluate the total amount of glucocorticoid prescribed to the patient and to provide appropriate treatment.

摘要

背景

长期使用糖皮质激素会通过减少骨量来增加骨折风险。本研究评估了髋部和椎体骨折与系统性糖皮质激素使用总量之间的关系。

方法

我们随机选择了 2006 年参加国家健康检查计划的 1896159 名 20 至 100 岁的人群。根据定义的每日剂量(DDD)计算了处方糖皮质激素的剂量。从索引日期起,将口服和胃肠外糖皮质激素的 6 个月总 DDD 相加,得出总 DDD。根据糖皮质激素总 DDDs,将受试者分为四组:非使用者(DDDs=0)、低剂量使用者(0<DDDs≤45)、中剂量使用者(45<DDDs≤90)和高剂量使用者(90<DDDs)。我们对他们进行了 2 年的随访。采用多变量 Cox 比例风险模型评估糖皮质激素总用量对髋部和椎体骨折的影响。

结果

更高的糖皮质激素使用量与椎体骨折风险增加相关。与非使用者相比,低剂量使用者组椎体骨折风险增加 1.39 倍,中剂量使用者组增加 1.94 倍,高剂量使用者组增加 2.43 倍。中剂量使用者髋部骨折风险增加 1.72 倍,高剂量使用者髋部骨折风险增加 3.28 倍。

结论

随着 6 个月糖皮质激素使用量的增加,髋部和椎体骨折的风险增加。为了预防骨折,医生有必要评估患者所开糖皮质激素的总量,并提供适当的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/7520587/67ca95511e6b/enm-2020-659f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验